Raiffeisen Bank International AG Has $1.37 Million Stock Holdings in Royalty Pharma PLC $RPRX

Raiffeisen Bank International AG increased its position in Royalty Pharma PLC (NASDAQ:RPRX) by 116.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 38,982 shares of the biopharmaceutical company’s stock after acquiring an additional 20,982 shares during the quarter. Raiffeisen Bank International AG’s holdings in Royalty Pharma were worth $1,374,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the last quarter. Financial Consulate Inc. bought a new position in shares of Royalty Pharma during the third quarter valued at $35,000. Richardson Financial Services Inc. acquired a new position in shares of Royalty Pharma during the third quarter worth $54,000. Farther Finance Advisors LLC lifted its holdings in shares of Royalty Pharma by 44.3% during the third quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 632 shares during the period. Finally, Fifth Third Bancorp grew its stake in shares of Royalty Pharma by 16.9% in the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 362 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling at Royalty Pharma

In other news, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Terrance P. Coyne sold 20,163 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $43.29, for a total transaction of $872,856.27. Following the transaction, the chief financial officer directly owned 22,885 shares in the company, valued at approximately $990,691.65. This represents a 46.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,034,602 shares of company stock valued at $41,353,043 in the last quarter. 18.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on RPRX shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Leerink Partners set a $45.00 price target on Royalty Pharma in a research note on Thursday, December 11th. Morgan Stanley restated an “overweight” rating and set a $61.00 price objective on shares of Royalty Pharma in a research report on Thursday, February 12th. Citigroup upped their target price on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Finally, Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma has an average rating of “Buy” and an average target price of $48.67.

Royalty Pharma Stock Performance

RPRX stock opened at $45.12 on Friday. The firm has a market cap of $26.05 billion, a PE ratio of 33.42 and a beta of 0.42. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The stock has a 50-day moving average price of $41.08 and a 200-day moving average price of $38.55. Royalty Pharma PLC has a 1-year low of $29.66 and a 1-year high of $46.14.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.33 by $0.13. The company had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. As a group, equities research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be given a dividend of $0.235 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 annualized dividend and a dividend yield of 2.1%. Royalty Pharma’s payout ratio is 65.19%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.